Salute e Benessere

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the…

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEBasel, August 7, 2025 –Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, today presents its financial results for the first half of 2025. Growth in this document is shown at constant currencies (CC)[1] unless stated otherwise. FINANCIAL RESULTS H1 2025H1 2024changeUSD mUSD mUSD %CC %CGR % [2] ...
Nasdaq GlobeNewswire
07/08/2025

Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global…

With the acquisition, Accord BioPharma, the U.S. specialty business of Intas, continues the commercialization of UDENYCA to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. UDENYCA offers three patient-friendly administration options—autoinjector (AI), on-body injector (OBI), and prefilled syringe…
PR Newswire
07/08/2025

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034)…

Key Takeaways from the Urothelial Carcinoma Market Report Key Takeaways from the Urothelial Carcinoma Market Report Discover the urothelial carcinoma new treatment @New Treatments for Urothelial Carcinoma Urothelial Carcinoma Market Dynamics The urothelial carcinoma market dynamics are expected to change in the coming years.Advancements in computational and bioinformatics platforms, along with various R&D practices, are enabling the development of the urothelial...
PR Newswire
06/08/2025

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and…

Key Takeaways from the CLK Inhibitors Market Report Key Takeaways from the CLK Inhibitors Market Report Discover which indication is expected to grab the major CLK inhibitors market share @CLK Inhibitors Market Report CLK Inhibitors Market Dynamics The CLK inhibitors market is gaining attention due to therising interest in alternative splicingas a therapeutic target. CLKs, particularly CLK1-4, regulate thephosphorylation of serine/arginine-rich (SR) proteins, which...
PR Newswire
06/08/2025

New Data Analyses from Groundbreaking Pivotal Bridge to HOPE Clinical Trial…

CHICAGO, Aug. 6, 2025 /PRNewswire/ -- Following the unveiling of 12-month follow-up results from the pivotal Bridge to HOPE trial during the World Transplant Congress (WTC) 2025 Plenary Session, additional analyses of the data demonstrate that Hypothermic Oxygenated Perfusion (HOPE), in conjunction with the VitaSmartTM Perfusion System, can provide significant cost-savings for hospital systems without compromising quality of care, and reduce the severity of organ rejection, including steroid…
PR Newswire
06/08/2025

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II…

Leuven, BELGIUM – August 6, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a transparency notification on August 6, 2025, from Atlas Special…
Actusnews Wire
06/08/2025

Biomarkers Market to Grow at a CAGR of 12.3% from 2025 to 2032 | SkyQuest…

Get a Free Sample Copy of the Report: https://www.skyquestt.com/sample-request/biomarkers-market Get a Free Sample Copy of the Report:https://www.skyquestt.com/sample-request/biomarkers-market Biomarkers Market Key Growth Drivers The biomarkers market is experiencing strong growth, driven by the rising demand for personalized medicine, where biomarkers play a key role in tailoring treatments based on individual genetic and molecular profiles. Increasing prevalence of chronic diseases...
PR Newswire
06/08/2025

Biopharmaceutical CDMO Market worth US$34.15 billion in 2030 with 8.8% CAGR |…

Browse in-depth TOC on "Biopharmaceutical CDMO Market" Browse in-depth TOC on "Biopharmaceutical CDMO Market" 422 - Tables 57 - Figures 380 - Pages By Service,the global biopharmaceutical contract manufacturing market is divided into four main service categories: manufacturing, formulation & fill-finish, packaging & labeling, and other services. The formulation & fill-finish segment accounts for the second-largest share of the market due to the rising demand…
PR Newswire
06/08/2025

Pharmaceutical Suppositories Market is expected to generate a revenue of USD…

The global Pharmaceutical Suppositories Market is expanding as healthcare providers seek effective, localized, and non-invasive drug delivery methods. Rising chronic diseases and pediatric/geriatric care needs are propelling demand across developed and emerging economies. The global Pharmaceutical Suppositories Market is expanding as healthcare providers seek effective, localized, and non-invasive drug delivery methods. Rising chronic diseases and pediatric/geriatric care needs are propelling...
PR Newswire
06/08/2025

Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum…

Cosmos Health Inc. (“Cosmos Health” or the “Company”)(NASDAQ:COSM), a diversified, vertically integrated global healthcare group, announced today that it has entered into a securities purchase agreement with a U.S.-based institutional investor for the issuance of up to $300 million in senior secured convertible promissory notes (the “Facility”), subject to the satisfaction or waiver of certain conditions, to support the launch of its Ethereum (ETH) digital asset treasury reserve...
Nasdaq GlobeNewswire
06/08/2025

Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for…

Click here to view the custom infographic of the Soligenix Inc. editorial. Clickhere to view the custom infographic of the Soligenix Inc. editorial. Chronic Conditions Demand Targeted Innovation Chronic rare diseases are becoming a major challenge for the aging population in the United States. As life expectancy rises, healthcare needs become more complex, especially for conditions that are long-lasting and hard to diagnose. With tens of millions of Americans living with a rare...
PR Newswire
06/08/2025

Continuity Biosciences Appoints Josephine Torrente and Joseph DeSimone, PhD to…

Dr. Joseph M. DeSimone Dr.Joseph M. DeSimone Executive Commentary "We are honored to welcome Josephine and Joe to our Board," said Bob Whitehead , Co-Founder and Executive Chairman of Continuity Biosciences. "Josephine's regulatory acumen and clear-eyed judgment are second to none. Joe is not only a visionary in drug delivery but also a trusted partner in our efforts through Focal Medical and PinPrint. Their expertise will be instrumental as we continue to scale our programs…
PR Newswire
06/08/2025

Alvotech Announces Webcast to Report Financial Results for the First Half of…

REYKJAVIK, ICELAND (August 6, 2025)– Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first half of the year ended June 30, 2025, after U.S. markets close on Wednesday, August 13, 2025. Alvotech will also conduct a conference call to present the financial results and recent business highlights on Thursday August 14, 2025, at 8:00 am...
Nasdaq GlobeNewswire
06/08/2025

Three-Day Longevity & Wellness Summit Set to Transform Health Innovation…

The summit will feature an impressive roster of international health and longevity experts, including: The summit will feature an impressive roster of international health and longevity experts, including: Additional speakers fromthe United States,United Kingdom, andMiddle Eastwill explore cutting-edge topics including biohacking and longevity, functional and precision medicine, nutritional science, AI-powered diagnostics, and emotional well-being optimization. In addition to...
PR Newswire
06/08/2025

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First…

FDA approves single-dose AJOVY ®(fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kilograms or more, offering a long-awaited monthly treatment option with in-office or at-home administration 1 AJOVY expands access across age groups as the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric episodic migraine prevention and migraine prevention in adults 1 This...
Nasdaq GlobeNewswire
06/08/2025

Forte Medical National Survey Announcement

Urinary Tract Infection (UTI) and prenatal screening: why do c14.2m UK women still suffer with up to 30% inaccuracy, failed hygiene and dignity? UK based Medical Technology company Forte Medical is launching a national survey of women in the UK, to ascertain their exposure to urine sampling retests and immediate empirical broad spectrum prescribing, triggered by traditional methods of specimen collection for Urinary Tract Infection and prenatal screening. The survey is independently...
Nasdaq GlobeNewswire
06/08/2025

Thyseed Newborn Baby Bottle with Bottom Vent Design: Clinically Proven to Reduce…

Targeting Feeding Challenges with Advanced Venting Technology Targeting Feeding Challenges with Advanced Venting Technology Colic and spit-up are common concerns for parents of newborns, whose digestive systems are still developing. To address this challenge, Thyseed's R&D team conducted thousands of simulations to develop the bottom vent design. During feeding, the bottle's internal pressure changes precisely control the vent's opening and closing, preventing air from mixing into milk...
PR Newswire
06/08/2025

Thyseed Is Set to Support Southeast Asian Families with Safer Infant Feeding…

Brand Commitment: Safety Built on Love Brand Commitment: Safety Built on Love Thyseed incorporates its Design From Love philosophy into every part of the brand experience. This love is shown in its strong focus on safety, believing that "every touchpoint matters in early development." Thyseed goes beyond global safety standards, using a full safety system from raw materials to finished products. All raw materials are checked for safety, production areas meet medical-grade…
PR Newswire
06/08/2025

Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant…

Bagsværd, Denmark, 6 August 2025-Financial report for the period 1 January 2025 to 30 June 2025 Operating profit increased by 25% in Danish kroner and 29% at constant exchange rates (CER) to DKK 72.2 billion.Sales in US Operations increased by 16% in Danish kroner (17% at CER). Sales in the US were positively impacted by...
Nasdaq GlobeNewswire
06/08/2025

ONWARD Medical Announces the Appointment of Lucas Buchanan to its Board of…

Buchanan is former CFO and COO of Silk Road Medical, where he successfully scaled a growth-stage medical device company, leading to an acquisition by Boston Scientific.Buchanan, formerly a venture capitalist with the Vertical Group, is also an active investor, advisor, and board member for several innovative medical device companies and healthcare investment funds.EINDHOVEN, The Netherlands, Aug.06, 2025(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX:...
Nasdaq GlobeNewswire
06/08/2025

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT)…

Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the United States Food and Drug Administration (FDA) has granted RMAT designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL). The RMAT designation was established under the U.S. 21st Century Cures Act to accelerate development and review...
Nasdaq GlobeNewswire
06/08/2025

Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.

Sanofi completes the acquisition of Vigil Neuroscience, Inc.Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc.(“Vigil”). This acquisition strengthens Sanofi’s early-stage pipeline in neurology with VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical study in patients with Alzheimer’s disease. In addition, the acquisition of Vigil’s preclinical pipeline will further strengthen Sanofi’s...
Nasdaq GlobeNewswire
06/08/2025

Bracco Imaging Receives Regulatory Approval in China for SonoVue® in the…

HyCoSy is a contrast-enhanced ultrasound (CEUS) procedure that helps identifying potential causes of female infertility related to blockage of the fallopian tubes or uterine abnormalities with a high level of diagnostic accuracy (1,2). Fallopian tube conditions, such as blockages, scarring, or other damage, are a leading cause of infertility, contributing to approximately 25–35 percent of cases of infertility among women in China (3). HyCoSy is a contrast-enhanced ultrasound (CEUS) procedure...
PR Newswire
06/08/2025

TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline…

Key Takeaways from the TYK2 Inhibitors Market Report Key Takeaways from the TYK2 Inhibitors Market Report Discover which indication is expected to grab the major TYK2 inhibitors market share @TYK2 Inhibitors Market Report TYK2 Inhibitors Market Dynamics The market for TYK2 inhibitors is emerging as a dynamic and rapidly evolving segment within thebroader immunology and inflammation therapeutics space. Unlike broader JAK inhibitors that often target multiple JAK subtypes...
PR Newswire
05/08/2025
Altri  Comunicati